The latest research study “Viral Vector Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global viral vector manufacturing market size reached a value of US$ 746.6 Million in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3,162.5 Million by 2027 exhibiting a CAGR of 25.40% during 2022-2027.
A viral vector is a piece of equipment utilized to deliver genetic materials into cells. It aids in curing genetic disorders and targeting and killing tumor cells. It is extensively used in scientific research, gene therapy, and vaccinology due to its assistance in treating metabolic diseases, heart defects and, neurogenerative disorders.
Download a Free PDF Sample for more detailed market insights: imarcgroup.com/viral-vector-manufacturing-m..
Viral Vector Manufacturing Market Trends and Drivers:
The market is primarily driven by the increasing number of clinical studies performed on viral vectors and the rising number of cancer patients. Additionally, they are bearers of virus disabling sequences and deliver HIV inhibiting transgenes to human hematopoietic stem cells (HSCs).
Besides this, the rising usage of viral vectors in novel drug delivery is propelling the market growth. Furthermore, the governments of various nations are launching campaigns to generate awareness about viral vector vaccines among the masses, which is escalating the demand for viral vector manufacturing.
Moreover, extensive investment in the research and development activities (R&D) by key market players and their indulgence in mergers and acquisitions (M&A) represent other major growth-inducing factors.
Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.
Global Viral Vector Manufacturing Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Viral Vector Manufacturing Companies:
Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: imarcgroup.com/viral-vector-manufacturing-m..
The report has segmented the market on the basis of region, type, disease, application and end user
Breakup by Type:
Adeno-associated Viral Vectors
Breakup by Disease:
Breakup by Application:
Breakup by End User:
Pharmaceutical and Biopharmaceutical Companies
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
134 N 4th St.
Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800